Side-by-side · Research reference

MOTS-cvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/68 cited

BPhase 3HUMAN-REVIEWED25/54 cited

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

MOTS-c

Survodutide

Primary target

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

—

Origin

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

—

Antibody development

—

02Dosage Protocols

Parameter

MOTS-c

Survodutide

Standard dose

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Once weekly

Lower / starter dose

2.5–5 mg / week

Recommended due to limited human data.

—

Evidence basis

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

4–12 weeks (experimental)

Optimal cycle length unknown.

—

Reconstitution

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

—

Timing

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

—

Half-life

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

—

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

MOTS-c

Survodutide

Primary fat target

Diet-induced / metabolic obesity; systemic fat utilization

Total body weight, visceral adipose tissue

Quantified reduction

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

—

IGF-1 impact

No direct IGF-1 pathway; AMPK-mediated

—

Effect on lean mass

High dose significantly ↑ lean mass in mice

—

Insulin sensitivity

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

—

Triglycerides

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

—

Glucose metabolism

Improved glucose tolerance; GLUT4 upregulationLee 2015

—

Effect reversibility

Unknown — no long-term follow-up data

—

Context dependency

No effect in normal-chow mice; requires metabolic stressReynolds 2021

—

Key publication

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

—

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

MOTS-c

Survodutide

Injection site reaction

Mild irritation (reported)

—

Fluid retention / Edema

Not reported

—

Glucose intolerance

Improves glucose toleranceLee 2015

—

Cardiovascular

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

—

Cancer risk

Contradictory data — some models suggest pro-proliferative effects

—

CNS / Neurological

Insomnia, headache (anecdotal reports)

—

GI symptoms

Nausea, stomach discomfort (reported)

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Evidence quality

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

—

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

MOTS-c

Survodutide

1. Reconstitution

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Injection site

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Needle

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

06Stack Synergy

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction

Survodutide

— no documented stacks